12
Participants
Start Date
April 30, 2007
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
Antacids (Mg-Al-based)
the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
Imatimib Mesylate (Gleevec®)
Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
University of Pittsburgh Cancer Institute / Clinical and Translational Research Center (Hillman Cancer Center and Montefiore University Hospital locations), Pittsburgh
Collaborators (1)
Novartis
INDUSTRY
University of Pittsburgh
OTHER